A61K 2039/6056
Antibodies
Official title: {Antibodies}
A61K2039/6056 (Antibodies) appears on 285 US grants and 486 published applications in this corpus.
Search patents in A61K- Granted patents
- 285
- Published applications
- 486
- Assignees
- 260
- Inventors
- 814
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 8 | 0 |
| 2001 | 1 | 0 |
| 2002 | 7 | 12 |
| 2003 | 0 | 9 |
| 2004 | 3 | 7 |
| 2005 | 0 | 9 |
| 2006 | 6 | 3 |
| 2007 | 1 | 4 |
| 2008 | 0 | 7 |
| 2009 | 3 | 10 |
| 2010 | 4 | 15 |
| 2011 | 11 | 27 |
| 2012 | 11 | 23 |
| 2013 | 13 | 18 |
| 2014 | 6 | 22 |
| 2015 | 14 | 24 |
| 2016 | 16 | 30 |
| 2017 | 13 | 30 |
| 2018 | 14 | 23 |
| 2019 | 33 | 23 |
| 2020 | 17 | 28 |
| 2021 | 17 | 27 |
| 2022 | 18 | 33 |
| 2023 | 15 | 41 |
| 2024 | 17 | 31 |
| 2025 | 21 | 22 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Therapeutic anticancer neoepitope vaccine4 Aug 2026US 12,697,377 B2Nykode Therapeutics ASA
- CD40 binding protein, bispecific conjugate thereof and method of treating cancer19 May 2026US 12,630,643 B2Strike Pharma AB
- Compositions and methods for membrane protein structure determination12 May 2026US 12,624,092 B2The Regents of the University of Michigan
- Recombinant proteins with CD40 activating properties17 Mar 2026US 12,576,147 B2Assistance Publique-HôPitaux De Paris (Aphp)
- Homodimeric protein constructs6 Jan 2026US 12,516,116 B2Nykode Therapeutics ASA
- Method of depleting target antigen-specific antibody from a patient by administering a fusion protein (seldeg) for selectively depleting antigen-specific antibodies27 Aug 2026US 2026/0250407 A1The Texas A&M University System
- Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody16 Jul 2026US 2026/0199346 A1Seagen Inc.
- Broadly neutralizing antibody-templated divalent immunogen vaccines16 Jul 2026US 2026/0201018 A1University of Hawaii
- Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof18 Jun 2026US 2026/0165980 A1Georgia Tech Research Corporation
- Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof9 Apr 2026US 2026/0097127 A1Cue Biopharma, Inc.
Most cited
By later US patents
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Receptor specific transepithelial transport of immunogens207US 6,086,875 ABrandeis University · 2000
- Compositions and methods for identifying antigens which elicit an immune response89US 6,500,641 B1Wake Forest University School of Medicine · 2002
- Zika RNA vaccines85US 10,449,244 B2ModernaTX, Inc. · 2019